Zacks Investment Research | Dec 21, 2021 10:27PM ET
Eli Lilly & Company industry .
Lebrikizumab was added to Lilly’s portfolio with the acquisition of Dermira in February 2020. The FDA had earlier granted Fast Track designation to lebrikizumab for moderate-to-severe AD in adult and adolescent patients.
Lebrikizumab is part of Lilly’s immunology pipeline, which also includes candidates like mirikizumab, being studied in late-stage studies for ulcerative colitis and Crohn's disease. Key marketed drugs in Lilly’s immunology portfolio include Taltz and Olumiant.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.